MYGN - MYRIAD GENETICS INC

4.36
0.080   1.835%

Share volume: 1,342,841
Last Updated: 03-30-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: -0.05%

PREVIOUS CLOSE
CHG
CHG%
$4.28
0.08
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
36%
Profitability 25%
Dept financing 32%
Liquidity 19%
Performance 52%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.63%
1 Month
-17.58%
3 Months
-29.11%
6 Months
-43.60%
1 Year
-50.85%
2 Year
-79.66%
Key data
Stock price
$4.36
P/E Ratio 
0.00
DAY RANGE
$4.20 - $4.38
EPS 
-$3.95
52 WEEK RANGE
$3.76 - $8.97
52 WEEK CHANGE
-$50.68
MARKET CAP 
573.264 M
YIELD 
N/A
SHARES OUTSTANDING 
93.508 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
0.64
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,555,830
AVERAGE 30 VOLUME 
$2,627,734
Company detail
CEO: Paul J. Diaz
Region: US
Website: myriad.com
Employees: 2,600
IPO year: 1995
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Myriad Genetics, Inc. develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers.

Recent news